[Open evaluation of a new anti-inflammatory analgesic drug: etodolac. Report of a clinical trial].
In a controlled clinical study the efficacy and tolerance of etodolac was evaluated in patients with orthopedic or traumatologic pathology. Twenty-four patients received one 200 mg tablet of the drug in the morning and two in the evening; patients were followed for a minimum of 60 days, and laboratory tests were done at the start, mid-term and after the end of treatment. For clinical evaluation, the following parameters were assessed: --pain during movement; --morning stiffness; --pain/sleep ratio; --global evaluation. For each of these parameters, a score was attributed at the beginning and end of treatment so as to obtain a quantitative assessment of the long-term pharmacological and clinical results. The patients benefitted from the treatment with specific effects on the parameters considered. Tolerance was good: only one patient had to abandon treatment. Compliance was fair, and the results were considered satisfactory even before the planned conclusion of the trial so that patients were advised to stop taking the drug once the therapeutic objective had been achieved. Overall judgment was very good as far as the pharmacological effect was concerned, and good as to tolerance and compliance.